Braskem (BAK) ownership transfer to IG4 Capital formally signed as Novonor exits controlling stake after judicial recovery

Braskem S.A. (B3: BRKM3, BRKM5, BRKM6; NYSE: BAK; LATIBEX: XBRK) has confirmed that voting control of Latin America’s largest petrochemical company is changing hands. On April 20, 2026, the company disclosed receipt of formal correspondence from Novonor S.A., NSP Investimentos S.A., and the Shine I Fundo de Investimento em Participações investment fund, confirming the execution of a Judicial Share Purchase and Sale Agreement dated April 17, 2026. The deal transfers approximately 50.1 percent of Braskem’s voting capital and 34.3 percent of its total share capital to a private equity vehicle backed by IG4 Capital, ending years of ownership uncertainty tied to the judicial recovery of Novonor, formerly the Odebrecht construction empire. Braskem’s NYSE-listed ADR closed at $3.57 on April 17, down 4.8 percent on the day, within a 52-week range of $2.32 to $5.30, reflecting a market still calibrating the pace and feasibility of the company’s operational turnaround.

How does the IG4 Capital acquisition of Braskem’s controlling stake from Novonor S.A. restructure Brazil’s petrochemical industry ownership?

The transaction resolves one of the most protracted ownership disputes in Brazilian corporate history. Novonor, which entered judicial recovery proceedings after the collapse of the Odebrecht construction empire, attempted to monetise its Braskem stake through multiple failed direct sale processes over several years. The mechanism now in play is more structurally inventive than a conventional share sale: IG4 Capital’s vehicle, Shine I Fundo de Investimento em Direitos Creditórios, first acquired the bank debt owed by the Novonor group, secured against Braskem shares held by NSP Investimentos S.A. Those credits, originally held by lenders including Itaú, Santander, Banco do Brasil, Bradesco, and BNDES, were purchased by the FIDC in December 2025. The Judicial Share Purchase and Sale Agreement executed April 17 now converts that credit position into equity through a structured debt-for-shares exchange, with IG4’s investment fund paying not in cash but in NSP Investimentos debentures, specifically 547.3 million first-series and 273.6 million second-series instruments under the 2nd Debenture Issue of NSP Investimentos S.A., tickers OSPI12 and OSPI22 respectively.

The practical consequence is that Novonor exits as controlling shareholder without a conventional cash exit, retaining only a 4 percent residual preferred stake in Braskem with no governance rights beyond statutory minimums. For a company in judicial recovery, this is a workable outcome: creditors get structured instruments, Novonor sheds operational liability, and IG4 Capital acquires governance control through a fund vehicle rather than a direct balance-sheet purchase. The architecture is unusual, but the regulator has followed it clearly, with Brazil’s Administrative Council for Economic Defence, CADE, having approved the concentration act in March 2026 without restrictions.

What conditions remain before the IG4 Capital and Petrobras joint control of Braskem can be formally completed?

The transaction is not yet closed, and the list of outstanding conditions is substantive enough to warrant attention. Three hurdles remain. The first is judicial authorisation within the framework of Novonor’s ongoing recuperação judicial proceedings, which requires the Brazilian court overseeing the bankruptcy process to sanction the share transfer. The second involves Petróleo Brasileiro S.A., which holds preemptive and tag-along rights under the existing Braskem shareholders’ agreement. Petrobras must formally decline to exercise those rights before the transaction can proceed to closing. The third concerns regulatory clearance from the European Commission under its Foreign Subsidies Regulation framework, which is still pending, though antitrust approvals from Brazil, Mexico, the United States, and the European Union on standard competition grounds have already been secured.

There is also a structural condition that could unwind the deal entirely: the Shine I investment fund is required to file a mandatory public tender offer, known locally as an OPA, with the Brazilian Securities and Exchange Commission to acquire up to all outstanding common and preferred shares of Braskem at the same terms as the principal transaction. If the CVM rejects the OPA registration, that rejection constitutes a resolutory condition that would dissolve the underlying agreement. This is not a formality. CVM review of the offer terms, pricing fairness, and the novel debt-for-debenture consideration structure will be substantive, and minority shareholders will be watching the OPA price closely given that Braskem’s ADR has traded significantly below Morningstar’s estimated fair value of $8.66 for much of the past year.

How will governance change at Braskem once IG4 Capital and Petrobras begin exercising shared control?

The new Braskem shareholders’ agreement between Shine I Fundo de Investimento em Participações and Petróleo Brasileiro S.A. will establish a balanced governance model that is structurally different from the previous arrangement, in which Novonor held unambiguous controlling authority. Upon closing, both parties will hold equal board representation and equal rights to appoint executive management, with a consensus requirement applying to all decisions at both the Board of Directors and General Meeting level. That consensus requirement is a significant constraint. It means neither IG4 Capital nor Petrobras can unilaterally impose strategic direction, capital allocation decisions, or management changes without the other’s agreement. For a company that needs rapid operational and financial restructuring, governance by consensus can be a source of friction, particularly if the two shareholders diverge on priorities.

IG4 Capital, through its advisory arm IG4 Sol Ltda., has already recruited turnaround specialists with backgrounds in logistics and water and sanitation to fill administrative and management roles at Braskem. That sectoral experience is relevant because Braskem’s core challenge is not product innovation but cost efficiency, capacity utilisation, and debt management across a multi-country production footprint. The company reported a going-concern warning in its 2025 annual audit, posted a R$9.9 billion net loss for fiscal 2025, and has been navigating a global petrochemical oversupply cycle that has compressed margins across its entire product mix. IG4 Capital’s turnaround thesis is that operational discipline and a stabilised balance sheet can restore Braskem’s value creation capacity, but the execution risk in a consensus governance structure should not be underestimated.

What does Braskem’s market position and financial distress mean for the new ownership structure’s credibility?

Braskem is Brazil’s largest petrochemical company and one of the leading polypropylene suppliers in the Americas, with 40 production plants across Brazil, the United States, Mexico, and Germany and sales touching more than 70 countries. Those are genuine competitive assets. The problem is that this footprint has been generating losses rather than returns through an extended cycle downturn. The 2025 earnings season confirmed weak utilisation rates against a backdrop of persistent Chinese overcapacity and sluggish global demand for resins and plastics. Braskem’s price-to-sales ratio of approximately 0.11 reflects how severely the market has discounted recovery prospects, while the Morningstar fair value estimate of $8.66 per ADR against a last-traded price near $3.57 suggests that the discount is large enough to represent either a genuine recovery opportunity or an indication that consensus estimates are too optimistic.

Citi upgraded Braskem to Neutral from Sell in April 2026, a marginal improvement in sentiment that coincided with the approach of deal formalisation. The stock’s 52-week range of $2.32 to $5.30 tells a story of deep uncertainty: the low reflects bankruptcy concerns that were real and publicly discussed as recently as early April, while the high reflects optimism around ownership resolution. The after-hours jump of 5.7 percent on April 17 to $3.77 following announcement of the signed agreement suggests the market views deal formalisation as a net positive, even if questions about OPA pricing, Petrobras consent, and European Commission approval keep a ceiling on enthusiasm.

The Mexican operations deserve a specific mention. Braskem Idesa, the company’s Mexican joint venture, has been separately evaluating debt restructuring options, a development that adds a layer of complexity for any incoming controlling shareholder. IG4 Capital’s ability to manage that process in parallel with the domestic Brazilian restructuring will be a near-term test of operational bandwidth.

What happens to minority shareholders of Braskem once the mandatory public tender offer is filed?

The OPA obligation is a critical protection for minority investors and warrants careful tracking. Under Brazilian corporate law and CVM Resolution No. 215, any change of control transaction triggers a mandatory offer to remaining shareholders at the same economic terms as the controlling block transaction. In this case, the consideration is not cash but Novonor-issued debentures, specifically the OSPI12 and OSPI22 instruments. Minority shareholders will need to evaluate whether those debentures represent fair value relative to a cash equivalent, and the CVM will scrutinise the terms before granting registration. If the OPA price or structure is deemed unfair, the CVM could reject registration, which would trigger the resolutory condition in the underlying purchase agreement and unwind the transaction.

The fact that Shine I Fundo de Investimento em Participações intends to file the OPA registration preferably before closing the principal transaction, rather than after, is strategically sensible. It removes one material closing condition from the post-signing timeline and reduces the risk of a protracted gap during which Braskem operates in ownership limbo. However, the CVM process is not a rubber stamp. Given the going-concern disclosures, the complexity of the consideration structure, and the political visibility of Brazil’s largest petrochemical company, the regulatory process is likely to be thorough.

Braskem has confirmed it will keep the market informed of all material developments as the transaction progresses toward closing.

Key takeaways: What the IG4 Capital acquisition of Braskem means for shareholders, competitors, and Brazil’s petrochemical sector

• Novonor S.A., formerly Odebrecht, exits as Braskem’s controlling shareholder after years of judicial recovery, retaining only a 4 percent residual stake with no governance rights beyond statutory minimums.
• IG4 Capital gains operational control through a debt-to-equity conversion structure, acquiring 50.1 percent of Braskem’s voting capital via its Shine I fund without deploying conventional cash consideration.
• Petróleo Brasileiro S.A. and IG4 Capital will co-govern Braskem on equal terms, with consensus required for all board and general meeting decisions, creating a potential governance friction point during a period that demands fast operational decisions.
• Three material conditions remain before closing: judicial authorisation in Novonor’s recuperação judicial, Petrobras formally waiving preemptive and tag-along rights, and European Commission Foreign Subsidies Regulation clearance.
• The mandatory OPA filing with the CVM represents both a minority shareholder protection and a resolutory condition: CVM rejection of the tender offer registration would unwind the entire transaction.
• Braskem’s 2025 fiscal year was marked by a R$9.9 billion net loss, a going-concern audit qualification, and weak global petrochemical pricing, meaning the incoming owners are acquiring a restructuring mandate, not a stable cash-generating asset.
• IG4 Capital has pre-positioned turnaround management talent across logistics and industrial operations to fill Braskem leadership roles, signalling that operational restructuring, not just financial engineering, is the stated thesis.
• The Mexican joint venture Braskem Idesa adds a second front of financial complexity, with debt restructuring options reportedly under evaluation in parallel with the main ownership transition.
• Braskem’s NYSE ADR at approximately $3.57 trades at a steep discount to analyst fair value estimates, suggesting either a meaningful recovery opportunity or persistent uncertainty about the execution path ahead.
• Brazil’s petrochemical sector, already under pressure from Chinese overcapacity, is watching this transaction closely: a successfully restructured Braskem would reinforce domestic capacity, while a prolonged governance dispute or OPA failure would add strategic uncertainty to an already stressed industry.